S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RKDA · Arcadia Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Arcadia Biosciences Inc (RKDA)
NASDAQ NMS - GLOBAL MARKET
Food Products
$0.15
+0.00
(+2.65%)
● At close: October 21 at 4:00:00 PM EDT
$0.15
-0.00
(-3.11%)
Overnight:
11:38:54 PM EDT
DAY'S RANGE
$0.15
$0.15
$0.15
52-WEEK RANGE
$0.15
$0.11
$5.23
What's happening
- RKDA is up 2.65% today, trading at $0.15. — Live quote
- It's trading within 3% of its 52-week low ($0.11). (Finnhub fundamentals)
- Volume today (11,053) is well below its 3-month average of 1,395,740. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.62 actual vs. $-0.55 estimated (+212.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-04-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RKDA
-92.27%
vs S&P 500
-105.05%
1-YEAR RETURN
RKDA
-96.89%
vs S&P 500
-111.45%
6-MONTH RETURN
RKDA
-88.58%
3-MONTH RETURN
RKDA
-77.32%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2025-10-26 (Q3 2025)
$0.62
Est. $-0.55
BEAT +212.6%
2025-07-26 (Q2 2025)
$0.02
Est. $-0.81
BEAT +102.5%
2025-04-26 (Q1 2025)
$1.90
Est. $-1.00
BEAT +290.1%
2025-01-26 (Q4 2024)
$-2.99
Est. $-0.91
MISS -229.4%
Valuation Measures & Ratios
Enterprise Value4-$3.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.08
Price / Book72.34
EV4 / Revenue-0.80
EV4 / EBITDA—
Profit Margin-234.53%
Operating Margin-80.11%
Return on Equity (ROE8)-339.85%
Return on Assets (ROA9)-169.00%
Avg Volume (3M)1,395,740
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.1M | $2.7M | $4.7M | $6.3M | $4.4M |
| P/E | -0.15 | -0.51 | -1.79 | -2.60 | -11.86 |
| Price/Sales | 0.39 | 0.54 | 0.85 | 1.14 | 0.88 |
| EV/Revenue | -0.40 | 0.35 | 0.65 | 0.89 | 0.26 |
| ROA | -241.86% | -101.22% | -30.46% | -30.95% | -2.89% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short88,752
Change from Prior Settlement+824.02%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -0.8% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -234.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -96.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RKDA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.1M | $1.3M | $1.5M | $1.2M | $1.5M | $1.3M | $987.0K |
| Operating income | -$496.0K | -$779.0K | -$1.2M | -$501.0K | $530.0K | -$1.8M | $2.0M | -$1.6M |
| Net income | -$6.3M | -$4.4M | $856.0K | -$4.5M | $2.6M | -$1.6M | $1.1M | -$2.4M |
| EPS (diluted) | $-2.09 | $-2.11 | $0.62 | $-3.26 | $1.90 | $-1.18 | $0.78 | $-1.78 |
| EPS (basic) | $-2.09 | $-2.11 | $0.63 | $-3.26 | $1.90 | $-1.18 | $0.78 | $-1.78 |
| Operating margin | -$34 | -$71 | -$88 | -$34 | $44 | -$115 | $152 | -$161 |
| Net margin | -$434 | -$399 | $66 | -$306 | $217 | -$105 | $81 | -$245 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.9M | $5.3M | $6.5M | $8.6M | $7.8M | $13.0M | $13.5M | $15.2M |
| Total liabilities | $5.3M | $2.4M | $2.4M | $3.1M | $3.3M | $4.1M | $7.3M | $5.1M |
| Stockholders' equity | — | — | — | — | — | — | $6.2M | $10.3M |
| Total current assets | $5.7M | $5.2M | $6.4M | $8.4M | $7.6M | $8.8M | $9.2M | $10.7M |
| Total current liabilities | $1.6M | $1.4M | $2.1M | $2.3M | $1.8M | $2.2M | $2.6M | $2.3M |
| Cash & equivalents | $4.2M | $954.0K | $259.0K | $1.1M | $1.4M | $3.2M | $4.2M | $3.9M |
| Marketable securities (current) | $0 | $2.8M | $4.3M | $4.8M | $3.1M | — | $0 | $2.6M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | $930.0K | $840.0K | $1.2M | $1.5M | $1.5M | $1.3M | $904.0K | $835.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $0 | $0 | $8.0K | $10.0K | $12.0K | $28.0K | $41.0K | $55.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $39.0K | $39.0K | $39.0K | $39.0K | $39.0K | $39.0K | $39.0K | $39.0K |
| Other non-current assets | $115.0K | $115.0K | $143.0K | $148.0K | $148.0K | $92.0K | $92.0K | $164.0K |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | $0 | $0 | $0 | $1.0M | $2.0M | $2.0M |
| Common stock & paid-in capital | $66.0K | $66.0K | $65.0K | $65.0K | $65.0K | $65.0K | $65.0K | $65.0K |
| Retained earnings | -$291.9M | -$285.6M | -$281.2M | -$279.9M | -$280.7M | -$276.3M | -$278.9M | -$274.8M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | $0 | $117.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$319.0K | -$1.1M | -$822.0K | -$257.0K | -$2.0M | -$1.6M | -$2.2M | -$1.8M |
| Investing cash flow | $0 | $0 | $0 | $0 | $250.0K | $500.0K | $2.5M | $180.0K |
| Financing cash flow | $3.5M | $1.8M | $0 | $1.0K | $0 | $5.0K | $0 | $4.0K |
| Free cash flow | — | — | -$822.0K | -$257.0K | -$2.0M | -$1.6M | -$2.2M | -$1.8M |
| Capital expenditures | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Share-based compensation | $14.0K | $15.0K | $156.0K | $53.0K | $86.0K | $78.0K | $374.0K | $155.0K |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $134.0K | $0 | -$406.0K | -$176.0K | $224.0K | $193.0K | $317.0K | $111.0K |
| Change in inventory | $90.0K | -$372.0K | -$244.0K | -$33.0K | $204.0K | $381.0K | $70.0K | -$180.0K |
| Purchases of investments | — | — | — | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M |
| Operating income | -$2.5M | -$3.6M | -$6.1M | -$14.0M | -$35.5M |
| Net income | -$2.3M | -$7.0M | -$14.0M | -$15.4M | -$14.7M |
| EPS (diluted) | $-1.71 | $-5.17 | $-11.29 | $-25.65 | $-27.56 |
| EPS (basic) | $-1.71 | $-5.17 | $-11.29 | $-25.65 | $-27.56 |
| Operating margin | -$51 | -$72 | -$137 | -$189 | -$524 |
| Net margin | -$48 | -$140 | -$314 | -$207 | -$216 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $6.5M | $13.5M | $19.7M | $28.9M | $43.9M |
| Total liabilities | $2.4M | $7.3M | $7.0M | $8.0M | $12.7M |
| Stockholders' equity | — | $6.2M | $12.8M | $21.0M | $31.1M |
| Total current assets | $6.4M | $9.2M | $15.0M | $25.4M | $35.4M |
| Total current liabilities | $2.1M | $2.6M | $3.6M | $4.2M | $5.0M |
| Cash & equivalents | $259.0K | $4.2M | $6.5M | $20.6M | $28.7M |
| Marketable securities (current) | $4.3M | $0 | $5.1M | $0 | — |
| Accounts receivable | — | — | — | — | $1.4M |
| Inventory | $1.2M | $904.0K | $837.0K | $2.3M | $4.4M |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $8.0K | $41.0K | $70.0K | $680.0K | $2.3M |
| Goodwill | — | — | — | — | — |
| Intangible assets | $39.0K | $39.0K | $39.0K | $40.0K | $484.0K |
| Other non-current assets | $143.0K | $92.0K | $164.0K | $165.0K | $180.0K |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | — | — | — | $270.0K | $264.0K |
| Long-term debt | — | — | — | — | $0 |
| Other non-current liabilities | $0 | $2.0M | $2.0M | $2.0M | $2.1M |
| Common stock & paid-in capital | $65.0K | $65.0K | $65.0K | $65.0K | $63.0K |
| Retained earnings | -$281.2M | -$278.9M | -$271.8M | -$257.9M | -$226.5M |
| Accumulated other comprehensive income (loss) | — | $0 | $101.0K | $0 | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$25.9M |
| Investing cash flow | $750.0K | $7.3M | -$4.3M | $1.4M | $16.6M |
| Financing cash flow | $6.0K | $9.0K | $5.5M | $4.5M | $21.9M |
| Free cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$26.9M |
| Capital expenditures | $0 | $16.0K | $5.0K | $72.0K | $1.0M |
| Share-based compensation | $234.0K | $512.0K | $717.0K | $1.1M | $1.5M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | -$165.0K | $762.0K | -$184.0K | -$592.0K | $40.0K |
| Change in inventory | $308.0K | -$550.0K | $2.4M | -$1.1M | $2.4M |
| Purchases of investments | — | $0 | $7.5M | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RKDA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-08-04 to 2025-02-03
Recent transactions
- Most recent: Kawakami Mark (Chief Financial Officer) — Open market purchase of 700 shares on 2025-02-03.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kawakami Mark | Chief Financial Officer | Open market purchase | 2025-02-03 | 700 |
| Schaefer Thomas J. | Chief Executive Officer | Open market purchase | 2025-02-03 | 700 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-02-03 | Kawakami Mark | Chief Financial Officer | Open market purchase | 700 | $2.49 |
| 2025-02-03 | Schaefer Thomas J. | Chief Executive Officer | Open market purchase | 700 | $2.49 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:13 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-15 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-04 | 8-K | 2026-08-31 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-07-01 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about RKDA (Arcadia Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Arcadia Biosciences files S-8 filing for Arcadia Biosciences stock
AD HOC NEWS · 2026-10-20 -
Which of Concorde International Group (NASDAQ:CIGL), Autolus Therapeutics (NASDAQ:AUTL), Arcadia Biosciences (NASDAQ:RKDA), MasterBeef Group (NASDAQ:MB) or TNL Mediagene (NASDAQ:TNMG) Fell 10% to 11% in Pre-Market?
kalkine.ca · 2026-10-16 -
These stocks that are showing activity before the opening bell on Friday.
ChartMill · 2026-10-16 -
Arcadia Biosciences files S-8 as Nasdaq tests Arcadia Biosciences stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
Which of BIO-key International (NASDAQ:BKYI), Arcadia Biosciences (NASDAQ:RKDA), SU Group Holdings (NASDAQ:SUGP), Nexentis Technologies (NASDAQ:NXTS) or Diginex (NASDAQ:DGNX) Is Declining Before the Bell Despite Quiet Tu
kalkine.ca · 2026-10-15 -
Arcadia Biosciences GAAP EPS of -$2.09, revenue of $1.44M
Seeking Alpha · 2026-08-13 -
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Yahoo Finance · 2026-08-13 -
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Yahoo Finance · 2026-06-13
No headlines in this category right now — try “All”.